Skip to content

Effect of early postoperative radiotherapy on linear scarring in a high-risk population: a single-center, randomized controlled clinical trial

Effect of early postoperative radiotherapy on linear scarring in a high-risk population: a single-center, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087785
Enrollment
Unknown
Registered
2024-08-05
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar

Interventions

Radiotherapy group:5 Gray*2 sessions (to be completed within 48h) of specified-dose superficial electron beam radiation therapy within 72h after surgery
Non-radiotherapy group:No special treatment for 72h after surgery

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 12 years and over 2. High-risk population 3. Incision is in a non-high-risk area** and the length of the incision is more than (including) 4cm 4. Skin type III/IV High-risk population: suspected possibility of pathological scarring, and/or history of pathological scarring, and/or family history of pathological scarring High-risk area: lower third of the face, shoulders, elbows, wrists, knees and ankles.

Exclusion criteria

Exclusion criteria: 1. Suffering from severe skin diseases such as psoriasis, scleroderma, etc. 2. Clinically significant or unstable systemic diseases that are excluded on the basis of their potential to interfere with the safety profile of the study results, including malignant neoplasms, uncontrolled diabetes mellitus, uncontrolled hypertension, unstable pneumonitis, renal or hepatic organic disease, unstable myocardial ischaemic disease, dilated cardiomyopathy, myocardial conduction abnormalities, or unstable cardiovascular disease. etc.

Design outcomes

Primary

MeasureTime frame
Incidence of pathological scarring;

Secondary

MeasureTime frame
Patient and Observer Scar Assessment Scale (POSAS) ;Security Indicators (adverse events);

Countries

China

Contacts

Public ContactXiaoxi Lin

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

linxiaoxi@126.com+86 137 0199 7136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026